ELISA for the quantitative and highly specific detection of human IgG antibodies against Coronavirus SARS-CoV-2 in human serum and plasma.

Benefits at a Glance:

  • Tests detect neutralizing antibodies directed against Receptor Binding
  • Domain (RBD) of spike protein of SARS-CoV-2 High specificity and sensitivity Results in 105 (IgG)  minutes
  • Ready-to-use reagents included
  • Tests are prepared for automation on open ELISA platforms
  • Developed, validated and manufactured in Marburg, Germany
  • EU: CE / IVD

Intended Use of DRG SARS-CoV-2 Antibody ELISAs

SARS-CoV-2 (RBD) IgG ELISA – EIA-6150 – quantitative

  • Detection of prior virus infection (> 14 days after infection)
  • Monitor vaccination success
  • Monitor vaccination efficiency
  • Support epidemiological studies for SARS-CoV-2

Assay Principle: Indirect ELISA

Objective: Quantitative Detection of IgG in Serum and Plasma

Assay Characteristics

  • Diagnostic Sensitivity: 100 % (for PCR-confirmed samples)
  • Method Comparison: 100% agreement to Roche Elecsys Anti-SARS-CoV-2
  • Diagnostic Specificity: 99.7 %
  • Intra-Assay Precision: 3.9 – 9.1%
  • Inter-Assay Precision: 8.4 – 12.0%
  • Excellent Linearity of Dilution: y = 1.004+1.4; R2= 0.994
  • Sample Matrix: Serum or Plasma (EDTA, lithium heparin or citrate plasma)
  • Total Assay Time: 75 minutes; short hands-on time
  • No dilution of samples necessary
  • Negative, Cut-off and Positive Control included
  • All reagents ready-to-use (except Wash Solution)
  • Validated according to CLSI Guidelines
  • EU: CE / IVD
  • This ELISA is validated for human samples, but could also be used for veterinary applications.